Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoTherapy ScienceFRA:30O -6.25%50 Quick Ratio is 13.22 as of Mar. 2026, which is 2% below its 10-year median of 13.45. GuruFocus rates FRA:30O with a GF Score™ of 50/100 and a GF Value™ of €0.08 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, OncoTherapy Science ranks better than 84.49% on this metric.
OncoTherapy Science has a quick ratio of 13.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for OncoTherapy Science's Quick Ratio or its related term are showing as below:
FRA:30O'
s Quick Ratio Range Over the Past 10 Years
Min: 2.07 Med: 13.45 Max: 27.78
Current: 13.22
During the past 13 years, OncoTherapy Science's highest Quick Ratio was 27.78. The lowest was 2.07. And the median was 13.45.
FRA:30O's Quick Ratio is ranked better than 84.49% of 1412
companies
in the Biotechnology industry
Industry Median: 3.595
vs FRA:30O: 13.22
OncoTherapy Science (FRA:30O) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
OncoTherapy Science Quick Ratio Related Terms
OncoTherapy Science Quick Ratio Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:30O vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, OncoTherapy Science's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Quick Ratio distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
OncoTherapy Science's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (FRA:30O) has a Quick Ratio of 13.22 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on OncoTherapy Science and its competitors. This is near median its historical median of 13.45. Over the past decade, OncoTherapy Science's Quick Ratio has ranged from 2.07 to 27.78. According to the industry distribution chart, OncoTherapy Science ranks #219 out of 1412 companies in the Biotechnology industry, placing it in the top 15.5%.
Is OncoTherapy Science's Quick Ratio too high?
OncoTherapy Science's current Quick Ratio of 13.22 is near median its 10-year median of 13.45. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 27.78. The Biotechnology industry median Quick Ratio is 3.60. OncoTherapy Science's value of 13.22 is 267.7% above this industry median. Based on the distribution chart, OncoTherapy Science ranks #219 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #219 out of 1412 companies for Quick Ratio. This places OncoTherapy Science in the top 16% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. OncoTherapy Science's value of 13.22 is 267.7% above this benchmark. Historically, OncoTherapy Science's own Quick Ratio has ranged from 2.07 to 27.78 over the past decade. While the company's 10-year median is 13.45 vs. the industry median of 3.60, OncoTherapy Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoTherapy Science's current Quick Ratio of 13.22 is 267.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current Quick Ratio is 13.22, which is near median its own 10-year median of 13.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (FRA:30O) is currently considered Fairly Valued. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 3.1% above its estimated fair value. The current Quick Ratio is 13.22, which is near median its 10-year median of 13.45 and 267.7% above the Biotechnology industry median of 3.60. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current Quick Ratio is 13.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (FRA:30O) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of €0.08 is trading 3.1% above its estimated GF Value™ of €0.08.
GuruFocus considers OncoTherapy Science to be Fairly Valued.
Key valuation signals for FRA:30O:
Quick Ratio: 13.22 (near median its 10-year median of 13.45)
GF Value™: €0.08 vs. price of €0.08 (3.1% above fair value)
Industry Position: 267.7% above the Biotechnology median (#219 of 1412)
No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for FRA:30O
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:30O has been successfully added to your 
